论文部分内容阅读
腹腔及静脉注入人白血病细胞HL 6 0建立人白血病异种移植模型 ,采用流式细胞仪检测HL 6 0细胞表面标志CD33、DNA含量及周期分布 ,及病理组织学检查观察其生长特性。结果显示 ,实验接种的HL 6 0细胞在放射线处理或未处理的SCID小鼠体内均能生长 ,发生全身性白血病。 3周时外周血即可见白血病细胞浸润 ,受累肝、脾增生期细胞比例增加 ,iv接种 5× 10 6HL 6 0细胞 ,在发病晚期 ,骨髓细胞中CD33+ 细胞占 3 79%和 2 97% ;ip接种 1 0× 10 7的SCID小鼠 ,其骨髓细胞中CD33+ 率为 12 32 %。提示HL 6 0 /SCID小鼠模型为良好的肿瘤体内研究模型 ,以CD33阳性率判断模型中肿瘤细胞浸润指标能快速、客观地判断病情。
The human leukemia cell line HL 60 was injected intraperitoneally and intravenously to establish a human leukemia xenograft model. Flow cytometry was used to detect the surface marker CD33, DNA content and the cycle distribution of HL 60 cells, and histopathological examination was performed to observe the growth characteristics. The results showed that experimentally inoculated HL 60 cells were able to grow in both irradiated and untreated SCID mice and systemic leukemia developed. At the 3rd week, leukemia cells infiltrated in peripheral blood, the proportion of cells in affected liver and spleen hyperplasia increased, and iv inoculated with 5×10 6 HL 60 cells. In the late stage of disease, CD33+ cells accounted for 3 79% and 297% of bone marrow cells. Inoculation of 10×10 7 SCID mice resulted in a CD33+ rate of 1232% in bone marrow cells. It is suggested that the HL 60/SCID mouse model is a good tumor in vivo research model. Judging the CD33 positive rate in judging the tumor cell infiltration index in the model can quickly and objectively judge the disease condition.